[Inhibitor development against FVIII in previously treated patients with haemophilia A. A retrospective data collection].

Institut für Thrombophilie und Hämostaseologie, Praxis Dr. med. Hartmut Pollmann, Loerstraße 19, 48143 Münster.
Hamostaseologie (Impact Factor: 1.59). 11/2010; 30 Suppl 1:S37-9.
Source: PubMed

ABSTRACT In a retrospective study 118 haemophilia A patients from two treatment centres (Berlin and Muenster) were evaluated with respect to safety, i. e. inhibitor development, and efficacy of bleeding control of recombinant FVIII products. During approx. 57 thousand injections with more than 87 million I.U. rFVIII no de novo inhibitor was observed in patients previously treated with pFVIII after switch to a recombinant product. A total of 75 thousand injections with more than 111 million I.U. FVIII had been applied during the investigation period of 14 years. Before as well as after switch of the product type bleeding episodes could be controlled with one to two injections per bleed. Conclusion: According to our results equal safety and efficacy of plasma derived and recombinant FVIII products can be assumed.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of neutralizing antibodies to factor VIII (FVIII) is the most serious complication of therapy for haemophilia A. There is now excellent documentation that a large number of both genetic and environmental factors contribute to the risk of FVIII inhibitor incidence. One of the environmental factors that has been proposed as an influence on this complication is the occurrence of FVIII product switching. There are only a small number of clinical studies that have addressed this question, and thus, the amount of objective information available to assess this association is limited. In this review, in addition to summarizing past evidence pertinent to this subject, we present the results of a complementary strategy, a Delphi analysis, to add to the considerations of product switching and FVIII immunogenicity. With the imminent arrival in the clinic of several new FVIII products, the haemophilia community must be prepared to collect prospectively controlled data to better address this important management issue.
    Haemophilia 03/2014; 20(2):200-6. DOI:10.1111/hae.12283 · 2.47 Impact Factor